Publications (13) Publications in which a researcher has participated

filter_list Pharmacology (medical)

2023

  1. Tolerance and Adherence of Patients with Chronic Chagas Disease Treated with Benznidazole

    Revista da Sociedade Brasileira de Medicina Tropical, Vol. 56

2019

  1. A Parasite Biomarker Set for Evaluating Benznidazole Treatment Efficacy in Patients with Chronic Asymptomatic Trypanosoma cruzi Infection

    Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 10

2012

  1. Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cutoff values for echinocandins, amphotericin B, flucytosine, and six Candida species as determined by the colorimetric sensititre yeastone method

    Journal of Clinical Microbiology, Vol. 50, Núm. 12, pp. 3921-3926

2010

  1. Antimicrobial resistance among respiratory pathogens in Spain: Latest data and changes over 11 years (1996-1997 to 2006-2007)

    Antimicrobial Agents and Chemotherapy, Vol. 54, Núm. 7, pp. 2953-2959

2009

  1. Actividad in vitro de fosfomicina frente a enterobacterias de origen urinario productoras de betalactamasas de espectro extendido

    Revista Espanola de Quimioterapia, Vol. 22, Núm. 1, pp. 25-29

2004

  1. In vitro activity of older and newer fluoroquinolones against efflux-mediated high-level ciprofloxacin-resistant Streptococcus pneumoniae

    International Journal of Antimicrobial Agents, Vol. 24, Núm. 2, pp. 185-187

2003

  1. Sensibilidad a antimicrobianos de aislamientos clínicos de Pseudomonas aeruginosa en Murcia

    Revista Espanola de Quimioterapia, Vol. 16, Núm. 4, pp. 444-449

2002

  1. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones

    Antimicrobial Agents and Chemotherapy, Vol. 46, Núm. 2, pp. 413-419

  2. In vitro activity of linezolid, synercid and telithromcin against genetically defined high level fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus

    International Journal of Antimicrobial Agents, Vol. 20, Núm. 1, pp. 61-64

2001

  1. Molecular diversity of quinolone resistance in genetically related clinical isolates of Staphylococcus aureus and susceptibility to newer quinolones

    Journal of Antimicrobial Chemotherapy, Vol. 47, Núm. 2, pp. 157-161

2000

  1. Actividad in vitro de nuevas quinolonas frente a cepas clínicas de Staphylococcus aureus silvestres y con mutaciones caracterizadas e n gyrA, gyrB y grlA

    Revista Espanola de Quimioterapia, Vol. 13, Núm. 3, pp. 271-275

1999

  1. In vitro activities of 13 fluoroquinolones against Staphylococcus aureus isolates with characterized mutations in gyrA, gyrB, grlA, and norA and against wild-type isolates

    Antimicrobial Agents and Chemotherapy, Vol. 43, Núm. 4, pp. 966-968

1997

  1. LDI amplifications in Leishmania

    Parasitology Today, Vol. 13, Núm. 9, pp. 342-348